Cardiol Therapeutics (CRDL) Other Non-Current Liabilities (2020 - 2026)

Cardiol Therapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (changed N/A YoY), and the FY2023 full-year result was $2.6 million, changed 0.29% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $2.1 million, down from $2.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $4.3 million in Q2 2022, with the low at $2.1 million in Q1 2026.
• Historically, Other Non-Current Liabilities has averaged $2.9 million across 4 years, with a median of $2.6 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities rose 4.79% — and 2023, when it sank 39.65%.
• Cardiol Therapeutics' Other Non-Current Liabilities stood at $2.6 million in 2022, then decreased by 0.29% to $2.6 million in 2023, then rose by 1.03% to $2.6 million in 2024, then decreased by 21.23% to $2.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.1 million (Q1 2026), $2.6 million (Q1 2024), and $2.6 million (Q4 2023), per Business Quant data.